Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice-Reference-Cited by-同舟云学术

Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice

Published:1992-12-11 Issue:5089 Volume:258 Page:1795-1798
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Mizoguchi Hiromoto¹,O'Shea John J.²,Longo Dan L.¹,Loeffler Cynthia M.³,McVicar Daniel W.²,Ochoa Augusto C.³

Affiliation:

1. Office of the Associate Director, Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702.

2. Laboratory of Experimental Immunology, Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702.

3. Immunotherapy Laboratory, Program Resources, Inc.-DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference45 articles.

1. ALLISON, J.P., STRUCTURE, FUNCTION, AND SEROLOGY OF THE T-CELL ANTIGEN RECEPTOR COMPLEX, ANNUAL REVIEW OF IMMUNOLOGY 5: 503 (1987).

2. ALTMAN, A, LYMPHOCYTE-T ACTIVATION - A BIOLOGICAL MODEL OF SIGNAL TRANSDUCTION, CRITICAL REVIEWS IN IMMUNOLOGY 10: 347 (1990).

3. BRODER, S, SUPPRESSOR-CELL NETWORK IN CANCER .1. (1ST OF 2 PARTS), NEW ENGLAND JOURNAL OF MEDICINE 299: 1281 (1978).

4. BUFERNE, M, ROLE OF CD3-DELTA IN SURFACE EXPRESSION OF THE TCR/CD3 COMPLEX AND IN ACTIVATION FOR KILLING ANALYZED WITH A CD3-DELTA-NEGATIVE CYTOTOXIC LYMPHOCYTE-T VARIANT, JOURNAL OF IMMUNOLOGY 148: 657 (1992).

5. BUSS, J.E., MOL CELL BIOL 4: 2705 (1984).

Cited by 600 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis;American Journal of Cancer Research;2024

2. The Interplay between T Cells and Cancer: The Basis of Immunotherapy;Genes;2023-04-28

3. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab;Journal of Clinical Oncology;2023-02-10

4. Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression;Biochemical and Biophysical Research Communications;2022-12

5. Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer;Frontiers in Oncology;2022-09-30